GCKR

OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders

Retrieved on: 
Thursday, November 3, 2022
Health, Infectious Diseases, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Doctor of Philosophy, Abstract (summary), Associate, Research, Phase 1, 2021 Essex County Council election, Weight loss, Liver, Custom, Lipogenesis, Cincinnati, Respiration (physiology), Mouse, NASH, Safety, Pharmacokinetics, AMPK, IPSC, Non-alcoholic fatty liver disease, Northwest Hospital & Medical Center, Lipotoxicity, Liver X receptor, Patient, Institute of Liver and Biliary Sciences, TCA, AASLD, Pediatrics, Translation, Hepatocyte, Oxidative stress, Plasma, Dyslipidemia, Gilead Sciences, GCKR, De novo, DNL, Foundation, LDL, Tryptophan, Fatty liver disease, Center, Acquired generalized lipodystrophy, Lipid metabolism, Gene, Insulin resistance, Primate, ABCA1, MD, ABCG1, LXR, Pharmaceutical industry, Medical device, Vaccine, Dietary supplement, Rail profile

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the companys programs at AASLDs The Liver Meeting from November 4-8.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the companys programs at AASLDs The Liver Meeting from November 4-8.
  • There remains tremendous unmet medical need for patients with severe metabolic disorders, said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio.
  • I am truly excited about translating the data on OrsoBios compounds in HLOs derived from genetic subsets of patients to clinical studies in patients with severe metabolic disorders.
  • The following abstracts will be presented as poster presentations at The Liver Meeting, in Washington, D.C., November 4-8, 2022.

OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Pharmacology, Entrepreneurship, Liver, MD, Lipogenesis, Plasma, Steatosis, ABCG1, Acquisition, Mouse, Liver disease, Hypertriglyceridemia, Lipoprotein, IPSC, Respiration (physiology), Institute of Liver and Biliary Sciences, NASH, Fatty liver disease, Foundation, DNL, Lipid metabolism, ABCA1, LXR, Patient, GCKR, De novo, Acquired generalized lipodystrophy, Gilead Sciences, Gene, Dyslipidemia, Cholesterol, Abstract (summary), Pharmaceutical industry, Gum arabic, Dietary supplement, Doctor of Philosophy, Liver X receptor, Rail profile

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.
  • Our Phase 1 study is progressing well, and we look forward to the continued development of TLC-2716 for the treatment of severe dyslipidemias in 2023.
  • I am truly excited that OrsoBio is progressing TLC-2716 into the clinic to unlock the potential of this first-in-class compound for patients with severe dyslipidemias.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.